Simple research view

A · Agilent Technologies, Inc.

$143.12 -1.13% Sep 10 close

Detected setup Trend Only · Setup Score 60/100

Stand aside — setup invalidated

Setup score 60, but distribution days reach 5 or more — stand aside until the condition resets.

Ask about A

Switch to Advanced for indicator panels, raw grades, provenance, drawing tools, and full technical tables.

$A

Agilent Technologies, Inc.

Agilent Technologies, Inc. is a large-cap Medical Specialties company in the Health Technology sector with a market cap of $40B.

Health Technology Medical Specialties stock Stage 2 · Advancing Base 1

$143.12 latest close

Join to Watchlist $A Share card

Verdict · setup score 60/100 · data Sep 10 close · 1 session old

Stand aside — setup invalidated

Setup score 60, but distribution days reach 5 or more — stand aside until the condition resets.

Review six verdicts Inspect chart

Earnings

Normal technical setup

No sourced report date Event risk is not modelled for this symbol

Deterministic evidence

A-1.13%

Sector proxy · XLV-0.55%

Broad market · SPY-0.60%

Same completed session window ending 2026-09-10. A was -0.58 points vs XLV. -0.53 points vs SPY.

Session internals Mixed

Rule: direction and internals disagree — it met neither the strong nor the weak rule. Judged on internals, not on the size of the move.

Vs prior close-1.13% From the open-1.97% Range position64% GapNo gap

QQQ confirmationConfirming (-1.06%) SMH confirmationConfirming (-2.44%)

Price bars, sourced event fields, and benchmark math only. This can adjust displayed short-term conviction; it does not change the stored scanner score or readiness.

Ask a Legend to interpret this evidence → Commentary only — never scanner evidence or a sizing recommendation.

Price $143.12 -1.1% Sep 10 close

52W High $163.75 12.6% below high

Wks Since High 2w 1w today

Base Depth 10.0% 13.7% today

RS Rank 28 percentile of scan

SMA 50 $142.99

Avg Vol 2,148,587

Rel Vol (Sep 10) 0.71×

More stats

52W Low $108.35

Tight Wks 0

Base B1

SMA 200 $131.60

RS Line vs High -18.9%

RS Line Slope -1.6% ▼

Group Rank #25/58

ADR% 2.7%

ATR(14) $4.73 (3.3%)

Vol Pace (live) N/A

U/D Vol 1.14

A/D Days 20A / 11D

A/D Rating A+

VDU Bars 0/10 d

Position in 52-week range 63rdpercentile of the 52-week range

$108.35low

$163.75high

A Chart

Interactive price, volume, RS, RSI, and MACD charts are available after sign in.

Create a free account to load the full interactive chart for A.

Create Free Account

Technical Analysis Report Card

$A · $143.12 · as of 2026-09-10 · multi-factor read

/ 100

Technicals 40/100

Reference read from price & volume only — the verdict at the top of the page decides the action.

Trend · Daily / Weekly / Monthly

Daily ▬ Sideways / consolidating

Weekly ▬ Sideways / consolidating

Monthly ▬ Sideways / consolidating

Moving Averages

50-day$142.99 ↑

100-day$133.00 ↑

200-day$131.60 ↑

Bullish (50 > 200)

RSI (14)

Reading40.6 · Bearish

Bearish momentum — sellers in control.

MACD (12/26/9)

StateWeakening

Histogram-1.827

Weakening — MACD slipped below its signal line. Histogram contracting.

Bollinger Bands (20,2)

%B / Width1% · 11.2%

Near the lower band — under pressure or oversold.

Volume · Buyer vs Seller

Up/Down vol1.14 · Neutral

Rel volume0.71×

Balanced — up/down volume is roughly even; no clear hand. Recent volume is expanding versus its baseline.

Support & Resistance

R · $150.24swing level

R · $163.7552-week high

Price · $143.12now

S · $135.78swing level

S · $127.46swing level

S · $124.34swing level

Fibonacci · Uptrend swing

23.6%$150.68

38.2% ◄ price here$142.59

50.0%$136.05

61.8%$129.51

78.6%$120.21

Retracement support zones measured from the recent swing low up to the high.

The verdict is free. The trade plan is Pro.

Unlock the exact entry, stop-loss, profit target, and reward-to-risk for A — plus the full 500+ symbol scanner and Ask-the-Legends chat.

Start your 7-day free trial →

Above 200-day MA50/200 bullishRS 36 (laggard)

Want this read in a legend's voice? Ask a Legend about A

Generic technical analysis generated mechanically from price & volume — educational research only, not financial advice or a personalized recommendation. Levels are illustrative; confirm on your own chart. New to these terms? →

Legend Verdicts 6 methodology checks

Who would consider this setup, why it qualifies, and what blocks it — calculated from the same deterministic methodology rules used across Legend AI.

Council consensus: 4 of 6 legends are Watching — building, not yet a confirmed buy.

Minervini

Avoid

Minervini C

Trend-template read: fails 150-day MA > 200-day MA.

Passing evidence

1.1 Price > 150-day MA AND 200-day MAPrice $143.12, MA150 $128.17, MA200 $131.60

1.4 50-day MA > 150-day MA AND 200-day MAMA50 $142.99, MA150 $128.17, MA200 $131.60

Failing evidence

1.2 150-day MA > 200-day MAMA150 $128.17 vs MA200 $131.60

1.8 RS rank ≥ 70 (prefer ≥ 85)RS rank 36

6/10 checks

Method → Playbook → Ask →

O'Neil

Avoid

O'Neil D

CANSLIM read: fails C: Quarterly EPS acceleration ≥ 25%.

Passing evidence

A: Annual earnings & revenue qualityRev +6.7% | ROE 20.5%

N: Near 52-week high or RS line new high12.6% below high | RS line new high: False

Failing evidence

C: Quarterly EPS acceleration ≥ 25%+8.7% QoQ

L: RS rank ≥ 80 (IBD leadership)RS rank 36

3/8 checks

Method → Playbook → Ask →

Weinstein

Watch

Weinstein C

Stage-analysis read: Stage 2 is present; 2 supporting checks need improvement.

Passing evidence

Stage 2 (Advancing phase) confirmedStage 2 (Advancing)

Price above 30-week MA (200-day proxy)Price $143.12 vs MA200 $131.60

Failing evidence

Volume expansion above averageVolume ratio 0.71x

Relative strength ≥ 60RS 36

5/7 checks

Method → Playbook → Ask →

Livermore

Watch

Livermore B

Pivotal-point read: constructive evidence is present, but relative strength is unresolved.

Passing evidence

Price$143.12

Distance from 52-week high12.6% below high

Failing evidence

Relative strengthRS 36

Volume vs average0.71x

3/6 checks

Method → Playbook → Ask →

Darvas

Watch

Darvas B

Box-theory read: constructive evidence is present, but relative strength is unresolved.

Passing evidence

Price$143.12

Distance from 52-week high12.6% below high

Failing evidence

Relative strengthRS 36

Volume vs average0.71x

3/6 checks

Method → Playbook → Ask →

Wyckoff

Watch

Wyckoff B

Supply-and-demand read: constructive evidence is present, but relative strength is unresolved.

Passing evidence

Price$143.12

Distance from 52-week high12.6% below high

Failing evidence

Relative strengthRS 36

Volume vs average0.71x

3/6 checks

Method → Playbook → Ask →

Base & Breakout

Breakout follow-through

No active breakout tracked — Legend AI monitors daily for pivot-point breaks. What's a breakout?

Unlock Base & Breakout Tracking

RS Line vs SPY 52-week relative strength · blue = RS line · dashed = MA50 · dot = NH ▼ Falling

Accumulation / Distribution last 65 sessions · green = acc on high vol · red = dist on high vol Net +7 A+

Minervini · Grade Card

Fundamentals & leadership quality — Minervini’s published criteria · 4/7 met

B 4/7 criteria

Separate score from the Minervini Trend Template (6/8): the Trend Template grades the price structure, this grades the company & leadership (earnings, sales, margins, RS rank). A stock can ride a clean trend while its fundamentals lag, so the two often differ by design — they are not the same checklist.

✗ EPS acceleration ≥25% QoQ +9%

✗ Revenue growth ≥20% YoY +7%

✓ Gross margin ≥30% 54%

✓ ROE ≥17% 20%

✗ RS rating ≥80 (leadership) 36

✓ Stage 2 uptrend (Weinstein) Stage 2

✓ Within 25% of 52W high -12.6%

Method Playbook

Trade it like Weinstein EXACT LEVELS · PRO

Minervini O'Neil Livermore Weinstein Darvas Wyckoff

Weinstein C · Watch — The deterministic methodology check is Watch; wait for the failing or incomplete criteria to improve before the trigger can qualify.

Pivot

Pro level

Published-method rule: Use Stage 1 resistance and the rising 30-week moving average as the Stage 2 transition boundary.
Evidence: Canonical setup geometry is available with Pro.

Entry trigger

Pro level

Published-method rule: Require a Stage 2 breakout above resistance on expanding volume; avoid entries while the 30-week average is flat or falling.
Evidence: Canonical setup geometry is available with Pro.

Initial stop

Pro level

Published-method rule: Start below the breakout structure or Stage 1 support where a return to the base invalidates the Stage 2 transition.
Evidence: Canonical setup geometry is available with Pro.

Trail

Rule-based

Published-method rule: Trail beneath rising 30-week support or later higher swing lows while Stage 2 remains intact.
Evidence: Planned management rule; no stored stop or broker order is changed automatically.

Exit / invalidation

Pro level

Published-method rule: Exit on a decisive 30-week support failure or a Stage 3/Stage 4 transition; never treat a failed Stage 2 break as healthy consolidation.
Evidence: Canonical setup geometry is available with Pro.

Deterministic educational plan, not a recommendation. No order or stop is changed automatically. Method and sources →

The published-method workflow is public. Unlock exact pivot, entry, stop, target, and sizing with Pro →

Pattern Analysis

Trend Only

60 setup score

RS Score 36

Trend template 6/8

Why This Setup?

Trend Only · schematic

Gatekeeper 6/8 | Moderate trend (6/8) | Stage 2

The Universal Edge Check · context only

What the setup still has going for it, recorded for later. The verdict above stands — these principles do not overrule it.

1/7 universals met

A relative-strength leader — not met RS rank 28 — laggard
Risk is defined — not met No stop — undefined risk
Asymmetric reward — partly met No target set
Clear of earnings — partly met Report date unknown
Not chasing (in range) — partly met Pivot distance unknown
Volume confirms — partly met 0.7× average — light
In a confirmed uptrend — met Stage 2 · Trend template 6/8

Why these seven? → The Universal Edge

Minervini Trend Template

6/8

Grades the price structure — moving-average stacking, distance from the 52-week high/low, and relative strength above the ≥70 uptrend bar. This is the technical trend check; the company's fundamentals and ≥80 RS leadership are scored separately in the Grade Card.

Price above SMA 150 & 200 $143.12 vs SMA150 $128.17 / SMA200 $131.60

SMA 150 above SMA 200 SMA150 $128.17 vs SMA200 $131.60

SMA 200 trending up Slope +0.53 over 20 days

SMA 50 above SMA 150 & 200 SMA50 $142.99

Price above SMA 50 $143.12 vs SMA50 $142.99

30%+ above 52-week low +32.1% from $108.35

Within 25% of 52-week high -12.6% from $163.75

RS score above 70 RS 36

Fundamentals

52W Range

63%

Mkt Cap SEC

40.3B

EPS QoQ

+9%

Rev YoY

+7%

ROE

20%

Gross Margin

54%

D/E

0.50

EPS TTM

$4.57

P/E TTM

31.3x

Float

282M

Company

Company profile

Agilent Technologies, Inc.

A · NYSE · Health Technology · Medical Specialties

Weekly Context

Multi-timeframe signals from weekly bars

W. Trend

7/8

W. RS

W. Support

$108.35

W. Resist

$163.75

Weekly Structure

Trend Neutral

Tight Weeks 0

Confirmation Neutral

Scan History

9× streak

Sep 11

Trend Only ✓ Gate

Sep 11

Trend Only ✓ Gate

Sep 10

Wyckoff SOS ✓ Gate

43 0.0%

Sep 10

Wyckoff SOS ✓ Gate

42 0.0%

Sep 09

Trend Only ✓ Gate

56 -1.1%

Sep 09

Trend Only ✓ Gate

56 -1.1%

Get the full picture on A

Pro members see entry/stop/target levels, R:R ratios, intraday alerts, and every setup detected across 500+ symbols daily.

Start 7-Day Free Trial